Evidence map›Paper›PMID 28507318›Full record

SynthesisMolecular psychiatry2018

Cerebellar volume and cerebellocerebral structural covariance in schizophrenia: a multisite mega-analysis of 983 patients and 1349 healthy controls.

T Moberget, N T Doan, D Alnæs, T Kaufmann, A Córdova-Palomera, T V Lagerberg, J Diedrichsen, E Schwarz, M Zink, S Eisenacher and 13 more

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Molecular psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

130 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Chiari I malformation.Nature reviews. Disease primers · 2026
    Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Microstructural Alterations of the Cerebellum-Ventral Tegmental Area Pathways in First-Episode Psychosis.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

T MobergetNORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
N T DoanNORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
D AlnæsNORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
T KaufmannNORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
A Córdova-PalomeraNORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
T V LagerbergNORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
J DiedrichsenDepartment of Computer Science and Department of Statistical and Actuarial Sciences, Brain and Mind Institute, Western University, London, ON, Canada.
E SchwarzDepartment of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
M ZinkDepartment of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
S EisenacherDepartment of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
P KirschDepartment of Clinical Psychology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
E G JönssonNORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
H Fatouros-BergmanCentre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
L FlycktCentre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
KaSP
G PergolaGroup of Psychiatric Neuroscience, Department of Basic Medical Science, Neuroscience, and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy.
T QuartoGroup of Psychiatric Neuroscience, Department of Basic Medical Science, Neuroscience, and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy.
A BertolinoGroup of Psychiatric Neuroscience, Department of Basic Medical Science, Neuroscience, and Sense Organs, University of Bari 'Aldo Moro', Bari, Italy.
D BarchDepartment of Psychology, Washington University, St Louis, MO, USA.
A Meyer-LindenbergDepartment of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
I AgartzNORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
O A AndreassenNORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
L T WestlyeNORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Funding

Transcranial Direct Current Stimulation for Treatment of Auditory Verbal HalluciP20GM103472 · NIGMS · THE MIND RESEARCH NETWORK · PI BEDRICK, EDWARD J · 2012 to 2017
$14.3M
STRUCTURE, FUNCTION AND COGNITION IN SCHIZOPHRENIAP50MH071616 · NIMH · WASHINGTON UNIVERSITY · PI THOMPSON, PAUL A. · 2004 to 2008
$11.2M
NEURAL MECHANISMS OF SCHIZOPHRENIAP20RR021938 · NCRR · THE MIND RESEARCH NETWORK · PI HANLON, FAITH MARIE · 2008 to 2011
$9.4M
Human Translational Applications Core (HTA - Core) (7 of 8)PL1MH083271 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BILDER, ROBERT M · 2007 to 2011
$5.8M
Translational Methods/Facilities Core (TMF - Core) (8 of 8)PL1NS062410 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EVANS, CHRISTOPHER J. · 2007 to 2011
$4.6M
Translational Models of Memory and Cognitive Control (Component 5 of 8)RL1MH083270 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JENTSCH, J. DAVID · 2007 to 2011
$2.6M
Whole Genome Assoc. Analysis Strategies for Multi. PhenotypesRL1MH083268 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FREIMER, NELSON B. · 2007 to 2011
$2.1M
Consortium for Neuropsychiatric Phenomics-Coordinating Center (1 of 8)UL1DE019580 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BILDER, ROBERT M · 2008 to 2011
$1.9M
Memory Mechanisms and Mental DisordersRL1MH083269 · NIMH · YALE UNIVERSITY · PI CANNON, TYRONE D · 2007 to 2011
$1.8M
Response Inhibition and Dopamine Neurotransmission (RI) (4 of 8)RL1DA024853 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LONDON, EDYTHE DANICK · 2007 to 2011
$1.7M
Hypothesis Web Development for Neuropsychiatric Phenomics (6 of 8)RL1LM009833 · NLM · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PARKER, DOUGLASS STOTT · 2007 to 2011
$1.5M
Schizophrenia Data and Software Tool Federation using BIRN InfrastructureR01MH084803 · NIMH · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WANG, LEI · 2009 to 2011
$933k
NCRR NIH HHS P20 RR021938NIDA NIH HHS RL1 DA024853NIDCR NIH HHS UL1 DE019580NIGMS NIH HHS P20 GM103472NIMH NIH HHS P50 MH071616NIMH NIH HHS PL1 MH083271NIMH NIH HHS R01 MH084803NIMH NIH HHS RL1 MH083268NIMH NIH HHS RL1 MH083269NIMH NIH HHS RL1 MH083270NINDS NIH HHS PL1 NS062410NLM NIH HHS RL1 LM009833
6 · The paper itself

Abstract

Although cerebellar involvement across a wide range of cognitive and neuropsychiatric phenotypes is increasingly being recognized, previous large-scale studies in schizophrenia (SZ) have primarily focused on supratentorial structures. Hence, the across-sample reproducibility, regional distribution, associations with cerebrocortical morphology and effect sizes of cerebellar relative to cerebral morphological differences in SZ are unknown. We addressed these questions in 983 patients with SZ spectrum disorders and 1349 healthy controls (HCs) from 14 international samples, using state-of-the-art image analysis pipelines optimized for both the cerebellum and the cerebrum. Results showed that total cerebellar grey matter volume was robustly reduced in SZ relative to HCs (Cohens's d=-0.35), with the strongest effects in cerebellar regions showing functional connectivity with frontoparietal cortices (d=-0.40). Effect sizes for cerebellar volumes were similar to the most consistently reported cerebral structural changes in SZ (e.g., hippocampus volume and frontotemporal cortical thickness), and were highly consistent across samples. Within groups, we further observed positive correlations between cerebellar volume and cerebral cortical thickness in frontotemporal regions (i.e., overlapping with areas that also showed reductions in SZ). This cerebellocerebral structural covariance was strongest in SZ, suggesting common underlying disease processes jointly affecting the cerebellum and the cerebrum. Finally, cerebellar volume reduction in SZ was highly consistent across the included age span (16-66 years) and present already in the youngest patients, a finding that is more consistent with neurodevelopmental than neurodegenerative etiology. Taken together, these novel findings establish the cerebellum as a key node in the distributed brain networks underlying SZ.

Indexed as

AdultBrainBrain MappingCase-Control StudiesCerebellumCerebral CortexFemaleGray MatterHumansImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleMiddle AgedNeural PathwaysReproducibility of ResultsSchizophrenia

Identifiers

PMID28507318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.